Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,980

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Open access
Estes, Chris, Anstee, Quentin M., Arias-Loste, Maria Teresa, Bantel, Heike, Bellentani, Stefano, Caballeria, Joan, Colombo, Massimo, Craxi, Antonio, Crespo, Javier, Day, Christopher P., Eguchi, Yuichiro, Geier, Andreas, Kondili, Loreta A., Kroy, Daniela C., Lazarus, Jeffrey V., Loomba, Rohit, Manns, Michael P., Marchesini, Giulio, Nakajima, Atsushi, Negro, Francesco, Petta, Salvatore, Ratziu, Vlad, Romero-Gomez, Manuel, Sanyal, Arun, Schattenberg, Jörn M., Tacke, Frank, Tanaka, Junko, Trautwein, Christian, Wei, Lai, Zeuzem, Stefan, Razavi, Homie·2018·Journal of Hepatology
DOI 10.1016/j.jhep.2018.05.036
Open this paper in CoChat — free account

Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. METHODS: A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. RESULTS: If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0-30%), between 2016-2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15-56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. CONCLUSIONS: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. LAY SUMMARY: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2018.05.036

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 56

  1. Sanyal, 2010, Population-based risk factors and resource utilization for HCC: US perspective, Curr Med Res Opin, 26, 2183, 10.1185/03007995.2010.506375 · DOI · Paper page
  2. Loomba, 2013, The global NAFLD epidemic, Nat Rev Gastroenterol Hepatol, 10, 686, 10.1038/nrgastro.2013.171 · DOI · Paper page
  3. Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Gastroenterology, 142, 1592, 10.1053/j.gastro.2012.04.001 · DOI · Paper page
  4. 2016, Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, Diabetologia, 59, 1121, 10.1007/s00125-016-3902-y · DOI · Paper page
  5. Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 · DOI · Paper page
  6. Younossi, 2016, Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 · DOI · Paper page
  7. Younossi, 2015, Economic and quality-of-life implications of non-alcoholic fatty liver disease, Pharmacoeconomics, 33, 1245, 10.1007/s40273-015-0316-5 · DOI
  8. Younossi, 2015, Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease, J Clin Gastroenterol, 49, 222, 10.1097/MCG.0000000000000071 · DOI
  9. Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466 · DOI · Paper page
  10. Malcolm, 1959, Application of a technique for research and development program evaluation, Oper Res, 7, 646, 10.1287/opre.7.5.646 · DOI · Paper page
  11. Rinella, 2015, Nonalcoholic fatty liver disease: a systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370 · DOI · Paper page
  12. Kim, 2013, Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease, Clin Mol Hepatol, 19, 120, 10.3350/cmh.2013.19.2.120 · DOI
  13. Lazo, 2013, Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994, Am J Epidemiol, 178, 38, 10.1093/aje/kws448 · DOI · Paper page
  14. Caballeria, 2010, Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain, Eur J Gastroenterol Hepatol, 22, 24, 10.1097/MEG.0b013e32832fcdf0 · DOI
  15. Fan, 2009, Epidemiology of non-alcoholic fatty liver disease in China, J Hepatol, 50, 204, 10.1016/j.jhep.2008.10.010 · DOI · Paper page
  16. Ayonrinde, 2017, Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents, J Hepatol, 67, 568, 10.1016/j.jhep.2017.03.029 · DOI
  17. Ayonrinde, 2015, Childhood adiposity trajectories and risk of nonalcoholic fatty liver disease in adolescents, J Gastroenterol Hepatol, 30, 163, 10.1111/jgh.12666 · DOI
  18. Oddy, 2013, The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence, Am J Gastroenterol, 108, 778, 10.1038/ajg.2013.95 · DOI · Paper page
  19. Rinella, 2011, Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?, Hepatology, 54, 1118, 10.1002/hep.24634 · DOI
  20. Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x · DOI · Paper page
  21. Ground, 1982, Liver pathology in aircrew, Aviat Space Environ Med, 53, 14
  22. Grant, 2004, Nonalcoholic fatty liver disease, Ann Hepatol, 3, 93, 10.1016/S1665-2681(19)32100-3 · DOI
  23. Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 · DOI · Paper page
  24. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  25. Stepanova, 2013, Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD), Dig Dis Sci, 58, 3017, 10.1007/s10620-013-2743-5 · DOI · Paper page
  26. Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012 · DOI · Paper page
  27. Targher, 2016, Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis of observational studies, J Hepatol, 65, 589, 10.1016/j.jhep.2016.05.013 · DOI · Paper page
  28. Calori, 2011, Fatty liver index and mortality: the Cremona study in the 15th year of follow-up, Hepatology, 54, 145, 10.1002/hep.24356 · DOI · Paper page
  29. Musso, 2011, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Ann Med, 43, 617, 10.3109/07853890.2010.518623 · DOI · Paper page
  30. Kern B, Newsome P, Karam V, Adam R, Berlakovich G, Fritz J, et al. Nonalcoholic steatohepatitis as indication for liver transplantation in Europe. Do we choose the right organs for the right recipients? American Transplant Conference; 2015 May 4, 2015; Philadelphia, Pennsylvania; 2015.
  31. Marmur, 2010, Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome, Scand J Gastroenterol, 45, 60, 10.3109/00365520903384742 · doi:10.3109/00365520903384742
  32. Schutte, 2013, Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany, Digestion, 87, 147, 10.1159/000346743 · DOI
  33. Wong, 2014, Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S., Hepatology, 59, 2188, 10.1002/hep.26986 · DOI · Paper page
  34. Huang, 2013, The national program for deceased organ donation in China, Transplantation, 96, 5, 10.1097/TP.0b013e3182985491 · doi:10.1097/tp.0b013e3182985491
  35. Delmonico, 2013, A welcomed new national policy in China, Transplantation, 96, 3, 10.1097/TP.0b013e31829949fb · doi:10.1097/tp.0b013e31829949fb
  36. Wang, 2013, Responses to comments on “Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report”, Hepatobiliary Surg Nutr, 2, 309
  37. Portillo-Sanchez, 2015, High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels, J Clin Endocrinol Metab, 100, 2231, 10.1210/jc.2015-1966 · DOI · Paper page
  38. Chan, 2009, Diabetes in Asia: epidemiology, risk factors, and pathophysiology, JAMA, 301, 2129, 10.1001/jama.2009.726 · DOI · Paper page
  39. Huxley, 2008, Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension, Obes Rev, 9, 53, 10.1111/j.1467-789X.2007.00439.x · DOI · Paper page
  40. Wong, 2015, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States, Gastroenterology, 148, 547, 10.1053/j.gastro.2014.11.039 · DOI · Paper page
  41. Aberg, 2011, Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score, Liver Transpl, 17, 1333, 10.1002/lt.22388 · doi:10.1002/lt.22388
  42. Tacke, 2016, Liver transplantation in Germany, Liver Transpl, 22, 1136, 10.1002/lt.24461 · DOI
  43. Neff, 2011, The current economic burden of cirrhosis, Gastroenterol Hepatol (N Y), 7, 661
  44. Whalley, 2007, Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs, Clin Med (Lond), 7, 119, 10.7861/clinmedicine.7-2-119 · DOI
  45. Baumeister, 2008, Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation, Gastroenterology, 134, 85, 10.1053/j.gastro.2007.10.024 · DOI · Paper page
  46. Kanwal, 2016, Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans, Clin Gastroenterol Hepatol, 14, e301, 10.1016/j.cgh.2015.08.010 · DOI · Paper page
  47. Weinmann, 2014, Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry, J Clin Gastroenterol, 48, 279, 10.1097/MCG.0b013e3182a8a793 · DOI
  48. Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 · DOI · Paper page
  49. Juluri, 2011, Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease, J Clin Gastroenterol, 45, 55, 10.1097/MCG.0b013e3181dd1348 · DOI
  50. Alberti, 2004, Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop, Diabetes Care, 27, 1798, 10.2337/diacare.27.7.1798 · DOI · Paper page
  51. Fracanzani, 2008, Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002/hep.22429 · DOI · Paper page
  52. Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, e310, 10.1053/j.gastro.2015.04.043 · DOI · Paper page
  53. Loomba, 2014, Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study, Hepatology, 60, 1920, 10.1002/hep.27362 · DOI · Paper page
  54. Sanyal, 2015, Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop, Hepatology (Baltimore, MD), 61, 1392, 10.1002/hep.27678 · DOI · Paper page
  55. McPherson, 2017, Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis, Am J Gastroenterol, 112, 740, 10.1038/ajg.2016.453 · DOI · Paper page
  56. Afshin, 2017, Health effects of overweight and obesity in 195 countries over 25 years, The New England Journal of Medicine, 377, 13, 10.1056/NEJMoa1614362 · DOI · Paper page

Cited by

See all 1,980

Metadata

Authors
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., Eguchi, Y., Geier, A., Kondili, L. A., Kroy, D. C., Lazarus, J. V., Loomba, R., Manns, M. P., Marchesini, G., Nakajima, A., Negro, F., Petta, S., Ratziu, V., Romero-Gomez, M., Sanyal, A., Schattenberg, J. M., Tacke, F., Tanaka, J., Trautwein, C., Wei, L., Zeuzem, S., & Razavi, H.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2018-10
Volume
69
Issue
4
Pages
896-904
ISSN
0168-8278 (ISSN-L)
DOI
10.1016/j.jhep.2018.05.036
OpenAlex
W2806839461
Cited by
1,980
References
10
FWCI
94.09
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. https://app.cochat.ai/papers/10.1016/j.jhep.2018.05.036
The paper
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., Eguchi, Y., Geier, A., Kondili, L. A., Kroy, D. C., Lazarus, J. V., Loomba, R., Manns, M. P., Marchesini, G., Nakajima, A., . . . Razavi, H. (2018). Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2018.05.036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.